Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

NOVARTIS

(NOVN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
95.56(c) 95.4(c) 95.82(c) 94.56(c) 94.4(c) Last
3 208 228 3 560 943 4 854 962 6 500 927 13 816 520 Volume
-0.06% -0.17% +0.44% -1.31% -0.17% Change
More quotes
Financials (USD)
Sales 2020 50 155 M
EBIT 2020 14 834 M
Net income 2020 9 659 M
Debt 2020 20 142 M
Yield 2020 3,22%
Sales 2021 53 199 M
EBIT 2021 16 418 M
Net income 2021 11 047 M
Debt 2021 15 230 M
Yield 2021 3,35%
P/E ratio 2020 23,0x
P/E ratio 2021 19,6x
EV / Sales2020 4,76x
EV / Sales2021 4,39x
Capitalization 218 B
More Financials
Company
Novartis is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceutical products (79.5%): used to treat cardiovascular, respiratory, and dermatological diseases, gastrointestinal... 
Sector
Pharmaceuticals
Calendar
02/27Presentation
More about the company
Surperformance© ratings of Novartis
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVARTIS
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/20GlaxoSmithKline Invests $50 Million in Biotech Startup's Cell-Therapy Program
DJ
02/17NOVARTIS : European Commission Approves Novartis Eye-Disease Drug Beovu -- Updat..
DJ
02/17Carrols Restaurant Group Names Markus Hartmann as General Counsel
AQ
02/17NOVARTIS : European Commission Approves Novartis Eye-Disease Drug Beovu
DJ
02/12Maersk Names Patrick Jany CFO
DJ
02/11NOVARTIS, INCYTE : Capmatinib Gets FDA Priority Review
DJ
02/10Mereo BioPharma Shares Up 26% After Securing Up to $33 Million in Funding
DJ
02/10MEREO BIOPHARMA : Secures Up to $33 Million Funding; Shares Surge
DJ
02/10Mereo BioPharma ADSs Up 28% on Equity Financing From Novartis
DJ
02/06Drugmaker Sanofi expects further profit growth from narrowed focus
RE
02/05GSK profit falls short as cheap competition hits older drugs
RE
02/04NOVARTIS : Boston Pharmaceuticals Appoints Dr. Craig T. Basson, MD, PhD, as Chie..
AQ
02/04Takeda sees surprise full-year operating profit on post-merger savings
RE
02/04NOVARTIS : Two persons die in separate accidents on railway tracks
AQ
More news
News in other languages on NOVARTIS
02/21Bourse Zurich: le SMI termine dans le rouge, après avoir tenté un rebond
02/21Aktien Schweiz: Konjunktursorgen bremsen SMI auf hohem Niveau aus
02/21Bourse Zurich: le SMI toujours en baisse face au coronavirus
02/21Bourse Zurich: ouverture en baisse
02/21Bourse Zurich: ouverture attendue en baisse
More news
Analyst Recommendations on NOVARTIS
More recommendations
Stock Trading Strategies
NOVARTIS - 2019
The underlying trend is in force again
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Pharmaceuticals - NEC
Chart NOVARTIS
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 103,78  $
Last Close Price 96,45  $
Spread / Highest target 30,0%
Spread / Average Target 7,60%
Spread / Lowest Target -10,4%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS2.89%218 568
JOHNSON & JOHNSON1.71%395 024
ROCHE HOLDING AG10.08%300 195
MERCK AND COMPANY-9.47%209 636
PFIZER-8.50%197 679
NOVO NORDISK AS14.48%149 779